Identification of two novel BRCA1-partner genes in the DNA double-strand break repair pathway.

Abstract:

:M1775R and A1789T are two missense variants located within the BRCT domains of BRCA1 gene. The M1775R is a known deleterious variant, while the A1789T is an unclassified variant that has been analyzed and classified as probably deleterious for the first time by our group. In a previous study, we described the expression profile of HeLa G1 cells transfected with the two variants and we found that they altered molecular mechanisms critical for cell proliferation and genome integrity. Considering that the mutations in the BRCA1 C terminus (BRCT) domains are associated to a phenotype with an altered ability in the DNA double-strand break repair, we chose three of the genes previously identified, EEF1E1, MRE11A, and OBFC2B, to be tested for an homologous recombination (HR) in vitro assay. For our purpose, we performed a gene expression knockdown by siRNA transfection in HeLa cells, containing an integrated recombination substrate (hprtDRGFP), for each of the target genes included BRCA1. The knockdown of BRCA1, OBFC2B, MRE11A, and EEF1E1 reduces the HR rate, respectively, of 97.6, 28.6, 41.8, and 42.3 % compared to cells transfected with a scrambled negative control duplex and all these differences are statistically significant (P < 0.05; Kruskal-Wallis test). Finally, we analyzed the effect of target gene depletion both on HR that on cell survival after DNA-damage induction by ionizing radiation. The clonogenic assay showed that the down-regulation of the target genes reduced the cell survival, but the effect on the HR, is not evident. Only the BRCA1-siRNA confirmed the inhibition effect on HR. Overall these results confirmed the involvement of MRE11A in the HR pathway and identified two new genes, OBFC2B and EEF1E1, which according to these data and the knowledge obtained from literature, might be involved in BRCA1-pathway.

authors

Guglielmi C,Cerri I,Evangelista M,Collavoli A,Tancredi M,Aretini P,Caligo MA

doi

10.1007/s10549-013-2705-9

subject

Has Abstract

pub_date

2013-10-01 00:00:00

pages

515-22

issue

3

eissn

0167-6806

issn

1573-7217

journal_volume

141

pub_type

杂志文章
  • Staging efficacy of breast cancer with sentinel lymphadenectomy.

    abstract::Seventy-two patients underwent dye-guided or dye- and gamma probe-guided sentinel lymphadenectomy (SLND) followed by complete axillary lymph node dissection (ALND). The results of imprint cytology, frozen sections, and permanent sections of the sentinel lymph node (SLN) were compared to each other and to the histologi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006268426526

    authors: Noguchi M,Bando E,Tsugawa K,Miwa K,Yokoyama K,Nakajima K,Michigishi T,Tonami N,Minato H,Nonomura A

    更新日期:1999-09-01 00:00:00

  • The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis.

    abstract::Platinum agents such as cisplatin and carboplatin are DNA-damaging agents with activity in breast cancer (BC), particularly in the triple negative (TN) subgroup. The utility of platinum agents, in addition to standard neoadjuvant chemotherapy (NAC), is controversial. To assess the activity of platinum agents in patien...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析,评审

    doi:10.1007/s10549-014-2876-z

    authors: Petrelli F,Coinu A,Borgonovo K,Cabiddu M,Ghilardi M,Lonati V,Barni S

    更新日期:2014-04-01 00:00:00

  • Breast tumor DNA methylation patterns associated with smoking in the Carolina Breast Cancer Study.

    abstract:PURPOSE:Tobacco smoking is a risk factor in several cancers, yet its roles as a putative etiologic exposure or poor prognostic factor in breast cancer are less clear. Altered DNA methylation contributes to breast cancer development and may provide a mechanistic link between smoking and gene expression changes leading t...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4178-8

    authors: Conway K,Edmiston SN,Parrish E,Bryant C,Tse CK,Swift-Scanlan T,McCullough LE,Kuan PF

    更新日期:2017-06-01 00:00:00

  • A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer.

    abstract::Heat shock protein 90 (Hsp90) facilitates maturation and stability of HER2. Combining an Hsp90 inhibitor and trastuzumab has demonstrated anti-tumor effects in patients with HER2+ breast cancer. Adults with measurable, locally advanced or metastatic HER2+ breast cancer and prior trastuzumab treatment were enrolled in ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s10549-013-2510-5

    authors: Modi S,Saura C,Henderson C,Lin NU,Mahtani R,Goddard J,Rodenas E,Hudis C,O'Shaughnessy J,Baselga J

    更新日期:2013-05-01 00:00:00

  • Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases.

    abstract::Conflicting theories of epithelial carcinogenesis disagree on the clonal composition of primary tumors and on the time at which metastases occur. In order to study the spatial distribution of disparate clonal populations within breast carcinomas and the extent of the genetic relationship between primary tumors and reg...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9317-6

    authors: Torres L,Ribeiro FR,Pandis N,Andersen JA,Heim S,Teixeira MR

    更新日期:2007-04-01 00:00:00

  • Effect of chemotherapy on survival in metastatic breast cancer.

    abstract::In order to assess the impact of modern combination chemotherapy on overall survival of metastatic breast cancer patients, we retrospectively analysed survival data of those patients who presented with breast cancer and developed metastases at our clinic from 1971-78 inclusive. Our results indicate a trend towards imp...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01806751

    authors: Paterson AH,Szafran O,Cornish F,Lees AW,Hanson J

    更新日期:1981-01-01 00:00:00

  • Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial.

    abstract:PURPOSE:Ki-67 has been clinically validated for risk assessment in breast cancer, but the analytical validation and cutpoint-definition remain a challenge. Intraclass correlation coefficients (ICCs) are a statistical parameter for Ki-67 interobserver performance. However, the maximum degree of variance among pathologis...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-05112-9

    authors: Denkert C,Budczies J,Regan MM,Loibl S,Dell'Orto P,von Minckwitz G,Mastropasqua MG,Solbach C,Thürlimann B,Mehta K,Blohmer JU,Colleoni M,Müller V,Klauschen F,Ataseven B,Engels K,Kammler R,Pfitzner BM,Dietel M,Fasching

    更新日期:2019-08-01 00:00:00

  • The polymorphic CAG repeat of the androgen receptor gene: a potential role in breast cancer in women over 40.

    abstract::Previous investigations into the relationship of CAG-repeat lengths in the androgen receptor (AR) gene to female breast cancer (BC) have yielded somewhat confusing results. Decreased AR transactivational activity lowers androgen:estrogen balance, and may thereby effect functional hyperestrogenicity. This may promote t...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1012942910375

    authors: Elhaji YA,Gottlieb B,Lumbroso R,Beitel LK,Foulkes WD,Pinsky L,Trifiro MA

    更新日期:2001-11-01 00:00:00

  • Cytogenetic evaluation of 20 sporadic breast cancer patients and their first degree relatives.

    abstract::Many genetic abnormalities disclosed even in somatic cells like peripheral blood lymphocytes may mark footprint(s) of malignancy(ies). The present cytogenetic study on peripheral blood lymphocytes of sporadic breast cancer patients (n = 20) and their first degree relatives (n = 39) reports abnormalities of chromosomes...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1005951125574

    authors: Trivedi AH,Roy SK,Bhachech SH,Patel RK,Dalal AA,Bhatavdekar JM,Patel DD

    更新日期:1998-03-01 00:00:00

  • Effects of high-intensity interval training on vascular endothelial function and vascular wall thickness in breast cancer patients receiving anthracycline-based chemotherapy: a randomized pilot study.

    abstract:PURPOSE:The purpose of this study was to determine the effects of an 8-week high-intensity interval training (HIIT) intervention on vascular endothelial function, measured as brachial artery flow-mediated dilation (baFMD), and vascular wall thickness measured by carotid intima media thickness (cIMT) in breast cancer pa...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10549-019-05332-7

    authors: Lee K,Kang I,Mack WJ,Mortimer J,Sattler F,Salem G,Lu J,Dieli-Conwright CM

    更新日期:2019-09-01 00:00:00

  • Chlorpheniramine inhibits the synthesis of ornithine decarboxylase and the proliferation of human breast cancer cell lines.

    abstract::Proliferation of both mouse and human breast cancer cells was inhibited by chlorpheniramine (CPA) in a dose-response manner. At the beginning of the exponential phase of growth (two days after seeding), 250 microM CPA was able to reduce cell proliferation by 75% (in Ehrlich cell cultures) and 30% (in MCF-7 cultures). ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF00668208

    authors: Medina MA,García de Veas R,Morata P,Lozano J,Sánchez-Jiménez F

    更新日期:1995-08-01 00:00:00

  • Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer.

    abstract:PURPOSE:The present study evaluated whether morphological-measured stromal and intra-tumour tumour-infiltrating lymphocytes (TILs) levels were associated with gene expression profiles, and whether TILs-associated genomic signature (GS) could be used to predict clinical outcomes and response to therapies in several brea...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4502-3

    authors: Kochi M,Iwamoto T,Niikura N,Bianchini G,Masuda S,Mizoo T,Nogami T,Shien T,Motoki T,Taira N,Tokuda Y,Doihara H,Matsuoka J,Fujiwara T

    更新日期:2018-01-01 00:00:00

  • Trastuzumab improves tumor perfusion and vascular delivery of cytotoxic therapy in a murine model of HER2+ breast cancer: preliminary results.

    abstract::To employ in vivo imaging and histological techniques to identify and quantify vascular changes early in the course of treatment with trastuzumab in a murine model of HER2+ breast cancer. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) was used to quantitatively characterize vessel perfusion/permeabilit...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-016-3680-8

    authors: Sorace AG,Quarles CC,Whisenant JG,Hanker AB,McIntyre JO,Sanchez VM,Yankeelov TE

    更新日期:2016-01-01 00:00:00

  • The management of ductal carcinoma in situ of the breast: a screened population-based analysis.

    abstract:BACKGROUND:A recent SEER study identified significant variations in the care of women with DCIS, yet several potential confounding variables were not included. We report a patterns of care study of women with DCIS to better understand the gap between evidence-based knowledge and the management of DCIS. METHODS:We stud...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9302-0

    authors: Rakovitch E,Pignol JP,Chartier C,Hanna W,Kahn H,Wong J,Mai V,Paszat L

    更新日期:2007-03-01 00:00:00

  • Evaluating breast cancer risk projections for Hispanic women.

    abstract::For Hispanic women, the Breast Cancer Risk Assessment Tool (BCRAT; "Gail Model") combines 1990-1996 breast cancer incidence for Hispanic women with relative risks for breast cancer risk factors from non-Hispanic white (NHW) women. BCRAT risk projections have never been comprehensively evaluated for Hispanic women. We ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1900-9

    authors: Banegas MP,Gail MH,LaCroix A,Thompson B,Martinez ME,Wactawski-Wende J,John EM,Hubbell FA,Yasmeen S,Katki HA

    更新日期:2012-02-01 00:00:00

  • Lack of efficacy of xeroradiography to preoperatively detect axillary lymph node metastases in breast cancer.

    abstract::Xeroradiography of the axilla was performed in 132 patients with operable breast cancer to investigate the status of the axillary lymph nodes. Pathologic findings were correlated with the results of clinical examination and xeroradiographic findings. Xeroradiography does not appear to have improved our ability to iden...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01807590

    authors: Coopmans de Yoldi GF,Andreoli C,Costa A,Nessi R,Gilardoni L,Rasponi A

    更新日期:1983-01-01 00:00:00

  • Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer.

    abstract::Prognosis of early beast cancer is heterogeneous. Today, no histoclinical or biological factor predictive for clinical outcome after adjuvant anthracycline-based chemotherapy (CT) has been validated and introduced in routine use. Using DNA microarrays, we searched for a gene expression signature associated with metast...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-1003-z

    authors: Bertucci F,Borie N,Roche H,Bachelot T,Le Doussal JM,Macgrogan G,Debono S,Martinec A,Treilleux I,Finetti P,Esterni B,Extra JM,Geneve J,Hermitte F,Chabannon C,Jacquemier J,Martin AL,Longy M,Maraninchi D,Fert V,Birnb

    更新日期:2011-06-01 00:00:00

  • Atypical ezrin localization as a marker of locally advanced breast cancer.

    abstract::Locally advanced breast cancer (LABC) was initially characterized as a large primary tumor (≥5 cm), associated with or without skin or chest-wall involvement, fixed axillary lymph nodes, or disease spread to the ipsilateral internal mammary or supraclavicular nodes. Since 2002, LABC has been reclassified to include sm...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-2017-5

    authors: Arslan AA,Silvera D,Arju R,Giashuddin S,Belitskaya-Levy I,Formenti SC,Schneider RJ

    更新日期:2012-08-01 00:00:00

  • Candidate early detection protein biomarkers for ER+/PR+ invasive ductal breast carcinoma identified using pre-clinical plasma from the WHI observational study.

    abstract::Estrogen receptor (ER)-positive/progesterone receptor (PR)-positive invasive ductal carcinoma accounts for ~45 % of invasive breast cancer (BC) diagnoses in the U.S. Despite reductions in BC mortality attributable to mammography screening and adjuvant hormonal therapy, an important challenge remains the development of...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3554-5

    authors: Buas MF,Rho JH,Chai X,Zhang Y,Lampe PD,Li CI

    更新日期:2015-09-01 00:00:00

  • Progesterone receptors and human breast cancer.

    abstract::Estrogen receptor protein is known to be an important prognostic factor for patients with breast cancer. The presence of estrogen receptor correlates with response to endocrine therapy in patients with metastatic disease and is associated with prolonged disease-free and overall survival in patients with primary diseas...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/BF01803558

    authors: Clark GM,McGuire WL

    更新日期:1983-01-01 00:00:00

  • The relationship between the predicted risk of death and psychosocial functioning among women with early-stage breast cancer.

    abstract:PURPOSE:Many women with early-onset breast cancer experience adverse psychological sequelae which impact on their quality of life. We sought to correlate levels of anxiety and cancer-related distress in women with breast cancer shortly after surgery and one year after treatment with the estimated risk of death. METHOD...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05992-w

    authors: Metcalfe KA,Candib A,Giannakeas V,Eisen A,Poll A,McCready D,Cil T,Wright FC,Armel S,Ott K,Sun P,Narod SA

    更新日期:2020-11-10 00:00:00

  • BRCA testing and outcomes in women with breast cancer.

    abstract:MAIN PURPOSE:Germline BRCA mutations (BRCAm) strongly influence the risk of developing breast cancer. This study aimed to understand the role of BRCAm testing in affected individuals and to assess its impact on the outcome of BRCAm carriers compared to non-carriers (BRCAwt) with breast cancer. RESEARCH QUESTION:The re...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-06038-x

    authors: Stenehjem DD,Telford C,Unni SK,Bauer H,Sainski A,Deka R,Schauerhamer MB,Ye X,Tak CR,Ma J,Dalvi TB,Gutierrez L,Kaye JA,Tyczynski JE,Brixner DI,Biskupiak JE

    更新日期:2021-01-03 00:00:00

  • Predictors of time to death after distant recurrence in breast cancer patients.

    abstract:BACKGROUND:After experiencing a distant recurrence, breast cancer patients have a poor prognosis; fewer than 5% survive for ten or more years. However, the time to death is highly variable, ranging from a few months to many years. The purpose of this study is to identify, in a large hospital-based series of patients wi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-5002-9

    authors: Sopik V,Sun P,Narod SA

    更新日期:2019-01-01 00:00:00

  • Paget's disease of the breast: the experience of the European Institute of Oncology and review of the literature.

    abstract:BACKGROUND:Paget's disease of the breast is an uncommon presentation of breast malignancy, accounting for 1-3% of all the breast tumors and presents in different histopathologic patterns: in association with an underlying invasive or non invasive carcinoma, or without any underlying neoplasia. In the literature, differ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9880-5

    authors: Caliskan M,Gatti G,Sosnovskikh I,Rotmensz N,Botteri E,Musmeci S,Rosali dos Santos G,Viale G,Luini A

    更新日期:2008-12-01 00:00:00

  • CCND1 G870A polymorphism contributes to breast cancer susceptibility: a meta-analysis.

    abstract::Cyclin D1 (CCND1), a key cell cycle regulatory protein that governs the cell cycle progression from G1 to S phase, can promote cell proliferation or induce growth arrest and apoptosis. Since the identification of a well-characterized functional polymorphism, G870A in exon 4 of CCND1, several molecular epidemiological ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-008-0195-y

    authors: Lu C,Dong J,Ma H,Jin G,Hu Z,Peng Y,Guo X,Wang X,Shen H

    更新日期:2009-08-01 00:00:00

  • Phase I study of the tolerance and pharmacokinetics of toremifene in patients with cancer.

    abstract::Toremifene is a triphenylethylene derivative structurally and pharmacologically similar to tamoxifen. This Phase I trial assessed the safety, pharmacokinetics, anti-estrogenic, and estrogenic effects of toremifene at six dose levels (10, 20, 40, 60, 200, and 400 mg/day). The most common side-effects associated with th...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1007/BF01807140

    authors: Kohler PC,Hamm JT,Wiebe VJ,DeGregorio MW,Shemano I,Tormey DC

    更新日期:1990-08-01 00:00:00

  • Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors.

    abstract:PURPOSE:Discordance between HER2 expression in tumor tissue (tHER2) and HER2 status on circulating tumor cells (cHER2) has been reported. It remains largely underexplored whether patients with tHER2-/cHER2+ can benefit from anti-HER2 targeted therapies. METHODS:cHER2 status was determined in 105 advanced-stage patient...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05662-x

    authors: Wang C,Mu Z,Ye Z,Zhang Z,Abu-Khalaf MM,Silver DP,Palazzo JP,Jagannathan G,Fellin FM,Bhattacharya S,Jaslow RJ,Tsangaris TN,Berger A,Neupane M,Cescon TP,Lopez A,Yao K,Chong W,Lu B,Myers RE,Hou L,Wei Q,Li B,Cri

    更新日期:2020-06-01 00:00:00

  • Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment.

    abstract::The aim of this study is to evaluate the impact of CYP2D6 genotyping in predicting disease-free survival and toxicity in breast cancer patients treated with adjuvant tamoxifen. DNA from 91 patients was genotyped using the AmpliChip CYP450 GeneChip, Roche that facilitates the classification of individuals by testing 27...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-009-0328-y

    authors: Ramón y Cajal T,Altés A,Paré L,del Rio E,Alonso C,Barnadas A,Baiget M

    更新日期:2010-01-01 00:00:00

  • Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.

    abstract::Breast cancer is the most common cancer among women. It is estimated that 7% of women who have breast cancer will develop a subsequent second independent breast tumor within 10 years of the first. The status of estrogen (ER), progesterone (PR) and human growth hormone (HER2) receptors, individually and as phenotypic c...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-009-0469-z

    authors: Brown M,Bauer K,Pare M

    更新日期:2010-02-01 00:00:00

  • miR-106b-5p and miR-17-5p could predict recurrence and progression in breast ductal carcinoma in situ based on the transforming growth factor-beta pathway.

    abstract:PURPOSE:Ductal carcinoma in situ (DCIS) is well-known precursor of invasive ductal carcinoma (IDC). Parts of patients show recurrence as DCIS or IDC after local treatment, but there are no established markers predicting relapse. We analyzed changes in miRNA and oncogene expression during DCIS progression/evolution to i...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05192-1

    authors: Lee J,Kim HE,Song YS,Cho EY,Lee A

    更新日期:2019-07-01 00:00:00